Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

  • End date
    Jan 1, 2024
  • participants needed
  • sponsor
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Updated on 31 January 2022
karnofsky performance status


This phase II trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade II-IV glioma. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.



I. To determine the effect of intensity-modulated (IM)-stereotactic radiotherapy (SRT) on the incidence of wound infection (requiring oral/intravenous [IV] antibiotics or surgery), or wound dehiscence.


I. To determine the effect of IM-SRT on the incidence of titanium implants as palpable cranial defects due to scalp thinning.

II. To determine the effect of IM-SRT on the incidence of hair loss and recovery rate.

III. To determine the effect on quality of life (QoL) using European Quality of Life Five Dimension Five Level Scale Questionnaire (EQ-5D-5L).


I. To determine if treatment of Intensity-modulated stereotactic radiotherapy (IM-SRT) in patients with newly diagnosed grade II-IV gliomas can decrease the loss of scalp thickness in the coronal plane in T-1W magnetic resonance (MR) images.

Condition Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma
Treatment intensity-modulated radiation therapy, Quality-of-Life
Clinical Study IdentifierNCT03251027
SponsorSidney Kimmel Cancer Center at Thomas Jefferson University
Last Modified on31 January 2022


Yes No Not Sure

Inclusion Criteria

Patients must have histologically confirmed low or high grade glioma (grade II-IV)
Karnofsky performance status (KPS) >= 60
Patients must have recovered from the effects of surgery; there must be a minimum of 21 days from the day of surgery to the day of protocol treatment
Estimated survival >= 3 months
Labs considered acceptable per standard of care
Patient must sign a study specific informed consent form
Radiation treatment must begin >= 3 weeks and =< 8 weeks after surgery

Exclusion Criteria

Prior history of scalp radiation or intolerance to standard course of radiation treatment
Co-morbidities that would influence wound healing including diabetes (insulin dependent) or smoking (current ongoing use)
Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
Karnofsky performance status (KPS) < 60
Patient can't have magnetic resonance imaging (MRI) scan
Active collagen vascular disease
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note